financetom
Business
financetom
/
Business
/
Pershing Square proposes $900 million deal to increase Howard Hughes stake
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pershing Square proposes $900 million deal to increase Howard Hughes stake
Feb 18, 2025 8:26 PM

(Reuters) - Billionaire investor Bill Ackman's Pershing Square Capital Management said on Tuesday it would buy 10 million newly issued shares of Howard Hughes Holdings ( HHH ) for $900 million as it revised its proposal to the real estate developer.

Shares of Howard Hughes dipped 5% in extended trading.

Under the proposal, Ackman would become chairman and CEO of Howard Hughes, Pershing said, adding the company's current CEO, David O'Reilly, will lead its principal subsidiary, Howard Hughes Corp.

The proposal would take Pershing's stake in Howard Hughes to 48% from the 37.6% it currently owns and replaces a previous offer of $1 billion made in January that would have increased its stake to between 61% and 69%.

Howard Hughes said in a statement late on Tuesday that its special committee would evaluate the revised offer and determine an appropriate course of action.

Pershing Square's management team will not receive cash, equity or other compensation in the transaction, but requires Howard Hughes to pay a 1.5% annual fee of its market capitalization to Pershing under a services agreement.

Howard Hughes currently has a market capitalization of about $3.8 billion, according to LSEG data.

Pershing said it would finance the deal for Howard Hughes, which owns and manages commercial, residential and mixed-use real estate in the U.S., with cash on hand.

Earlier in the day, Ackman said in a post on X that Pershing would announce a potential transaction to create a "modern-day version of Berkshire Hathaway."

Ackman has been personally involved with Howard Hughes for a decade and stepped off the company's board in April after having served as its chairman since 2010.

(Reporting by Utkarsh Shetti in Bengaluru, Additional reporting by Pretish M J; Editing by Shilpi Majumdar and Anil D'Silva)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amazon Q2 Earnings Highlights: Double Beat, 'AI Progress Across The Board Continues'
Amazon Q2 Earnings Highlights: Double Beat, 'AI Progress Across The Board Continues'
Jul 31, 2025
Ecommerce giant Amazon.com Inc ( AMZN ) reported second-quarter financial results after market close Thursday. Here are the highlights. What Happened: Amazon ( AMZN ) reported second-quarter net sales of $167.7 billion, up 13% year-over-year. The net sales total beat a Street consensus estimate of $161.9 billion according to data from Benzinga Pro. Sales were broken down as follows: North...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Leggett & Platt Q2 sales beat estimates, EPS rises
Leggett & Platt Q2 sales beat estimates, EPS rises
Jul 31, 2025
Overview * Leggett & Platt ( LEG ) Q2 sales of $1.1 bln beat analyst expectations * Adjusted EPS for Q2 rises to $.30, up $.01 yr/yr * Co reduced debt by $143 mln, improving balance sheet Outlook * Leggett & Platt ( LEG ) maintains 2025 sales and adjusted EPS guidance Result Drivers * SOFT DEMAND - Volume decreased...
Corcept Therapeutics Q2 revenue misses estimates
Corcept Therapeutics Q2 revenue misses estimates
Jul 31, 2025
Overview * Corcept Q2 2025 revenue grows to $194.4 mln, missing analyst expectations, as per LSEG data * Net income for Q2 2025 slightly declines to $35.1 mln * The pharma company repurchased $115.4 mln of common stock in Q2 2025 Outlook * Corcept guides 2025 revenue at $850 mln to $900 mln * Company expects improved vendor performance to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved